All News

vaccination.jpg

H. Zoster Subunit Vaccine Efficacy with JAK Inhibitor Therapy

Jack Cush, MD

JAK inhibitors are known to increase the risk of herpes zoster infections between between 3-5 fold.  Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV). 

Read Article
computer screen safety

Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitor Treatment of Skin Disorders

Jack Cush, MD

A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the placebo

Read Article
RheumNow Podcast square

Methotrexate in OA (10.20.2023)

Jack Cush, MD

Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.

Read Article
FDA,approved,stamp,blue

FDA Approves Bimekizumab for Plaque Psoriasis

Jack Cush, MD

UCB announced today that the US Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.

Read Article
RheumNow Podcast square

Sleep Apnea Smart Watches (10.13.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.

Read Article
FDA%20approved.jpg (keep)

FDA Approves IV Secukinumab

Jack Cush, MD

On Oct. 6, 2023, Novartis announced the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation of secukinumab (Cosentyx) for use in treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

Read Article
RheumNow Podcast square

PMR & Popeye's Spinach (10.6.2023)

Jack Cush, MD

Dr. Jack Cush reviews the big PMR reports from this week along with other journal reports from RheumNow.com.

Read Article
FDA has approved another ustekinumab biosimilar (Wezlana) as being interchangeable for use in adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. https://t.co/zbQKjmKgZh https://t.co/UuTDRgCBIV

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved Abatacept to Treat Juvenile Psoriatic Arthritis (JPsA) in patients aged 2 to 17 years. (JPsA) in patients aged 2 to 17 years. This expands the current indications for ABA use in RA, poly JIA, PsA, and GVHD. https://t.co/eAc8Dsyc3b https://t.co/uHJqhEvuPG

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today! https://t.co/1SjBiM7Daj https://t.co/w2cFcj85r5

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today! https://t.co/7OsdPYWukv https://t.co/QoCxR04bJD

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves Bimekizumab for Plaque Psoriasis UCB announced today that the FDA has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy. https://t.co/BqeSAAxtQb https://t.co/LFjzkmAC5w

Links:

Dr. John Cush RheumNow ( View Tweet)
Sleep problems in SpA & PsA? Study of 201 pts shows 43% of axSpA and 47% of PsA pts reported sleep problems. In both poor sleep assoc w/ dz activity. In axSpa it signif assoc w/ Dz activity (OR 8.45),biologic use (OR .24), & CRP levels (OR .16) https://t.co/7juI2Dghjh https://t.co/SxCaJgTmeQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/Eo4LMaTHxn https://t.co/abzlThasEN

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/IeobNWcM94 https://t.co/OMbhVwFCCt

Links:

Dr. John Cush RheumNow ( View Tweet)
Turkish study 1,134 PsA pts found mean Dx delay=35 mos (median: 12). 39% Dx w/in 3 mos, & 67% w/in 24 mos. Dx delay decr. over time: 60 to 24 mos (<2010 to 2015–2019). Dx delay factors: less education (OR 2.6), arthritis>PSO (1.7), LBP 1st (1.6)https://t.co/GYKPSaYWhU https://t.co/YYwaiQd5mJ

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves IV Secukinumab On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) https://t.co/zv7b98ZUjS https://t.co/1rXjYIbLpw

Links:

Dr. John Cush RheumNow ( View Tweet)
Registration is now open! Early bird pricing is available until 11/30/23. See you there! https://t.co/zjXyldwlyl https://t.co/CpQ00745c1

Links:

Dr. John Cush RheumNow ( View Tweet)
It's so important to diagnose psoriatic arthritis early. If you have psoriasis please join the HPOS study at https://t.co/xBBFj4npgo https://t.co/qBxDzr2IZZ

LauraCoates  ( View Tweet)

Sustained Efficacy of Bimekizumab in PsA BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, BKZ, in patients with active PsA and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52. https://t.co/JQ53JV0dvv https://t.co/RQoIXsVnOr

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×